# Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

> **NCT03443973** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 975 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Gantenerumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03443973
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-22
- **Primary completion:** 2022-09-23
- **Final completion:** 2022-11-28
- **Target enrollment:** 975 (ACTUAL)
- **Why stopped:** Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).
- **Last updated:** 2024-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03443973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03443973, "Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03443973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*